RxDoctor Payments Data

John Burbidge, DO

Family Medicine · Waco, TXNPI 1841277639

Payments from drug & device makers

$813in general payments, 2019–2025

Across 53 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$137
  • Astellas Pharma US Inc$123
  • Novartis$110
  • Lilly USA, LLC$108
  • Pfizer$61
  • AbbVie$49
  • plus $224 from 11 others

What the payments were for

  • Food & beverage$69986%
  • Education$11314%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$813 in reported general payments places this provider in the 55th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$114,895
Medicare patients
214
Services billed
3,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide91$103,714
MounjaroTirzepatide74$87,619
EliquisApixaban67$54,142
Tresiba Flextouch U-200Insulin Degludec39$39,085
JardianceEmpagliflozin44$35,987
Trelegy ElliptaFluticasone/Umeclidin/Vilanter52$35,792
MyrbetriqMirabegron29$26,207
JanuviaSitagliptin Phosphate16$24,791
TrulicityDulaglutide18$24,218
XareltoRivaroxaban16$15,815
LinzessLinaclotide28$14,937
Breo ElliptaFluticasone/Vilanterol19$10,997
Janumet XrSitagliptin Phos/Metformin Hcl11$10,992
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$9,872
GemtesaVibegron12$8,046

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$108$111,83892 claims
Novo NordiskOzempic$137$103,71491 claims
PfizerEliquis$61$54,14267 claims
GSKTrelegy Ellipta, Breo Ellipta$39$46,78971 claims
Astellas Pharma US IncMyrbetriq$123$26,20729 claims
Johnson & JohnsonXarelto$32$15,81516 claims
AbbVieLinzess$49$14,93728 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →